LinkOPH

SAN DIEGO — No significant difference in best correctedvisual acuity was seen when patients with diabetic macular edema at the time ofcataract surgery were given either triamcinolone or bevacizumab, according to aspeaker here.“The poorest visual outcomes are seen in those withdiabetic macular edema at the time of surgery,” said Salmaan Al-Qureshi, MBBS, FRANZCO, who presented 6-month resultsfrom the DiMECAT trial at the American Society of Retina Specialists annualmeeting. “Despite the advances in treatment, there is very little evidenceregarding the use of anti-VEGF or triamcinolone in cataract surgery.”

Read more →

The California federal judge overseeing Allergan’s insider trading lawsuit against Valeant Pharmaceuticals has set an Aug. 20 hearing date, according to a press release from Reuters.The lawsuit against a hostile takeover by Valeant and Pershing Square Capital Management hedge fund was filed by Allergan on Aug. 1.

Read more →

SAN DIEGO — Spectral-domain optical coherence tomography volume measurements of drusen and retinal pigment epithelium abnormal thinning may help stratify eyes with intermediate age-related macular degeneration to predict progression to advanced AMD.Drusen volume as seen on spectral-domain OCT (SD-OCT) wasable to predict progression to choroidal neovascularization, a speaker saidhere.

Read more →

SAN DIEGO — Higher doses of a novel small molecule underdevelopment offers potential as a future treatment for neovascular age-relatedmacular degeneration, according to early results of a phase 2 dose-escalationstudy. Pravin U. Dugel,MD, told colleagues at the American Society of Retina Specialists annualmeeting that ESBA 1008 met its primary endpoint of noninferiority at week 4 vs.ranibizumab (Lucentis, Genentech) in two of its highest doses being assessedfor safety and tolerability.

Read more →

SAN DIEGO — Optimal management of macular holes has long been debated, but some conclusions can be made, according to a speaker at the American Society of Retina Specialists annual meeting. Ron Adelman, MD, MPH, FACS, who presented results from the European Vitreoretinal Society Macular Hole Study, said despite the number of variables regarding technique and management among the 140 participating retina specialists in 28 countries, hole closure was achieved in 85.7% of 4,207 macular hole cases after more than 1 year of follow-up.

Read more →